Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S309000, C546S122000, C546S123000, C546S141000
Reexamination Certificate
active
06974822
ABSTRACT:
This invention provides compounds defined by Formula I:or a pharmaceutically acceptable salt thereof,wherein R1, Q, R2, R3, R4, and n are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.
REFERENCES:
patent: 6008243 (1999-12-01), Bender et al.
patent: 6656932 (2003-12-01), Picard et al.
patent: 2002/0086890 (2002-07-01), Levin et al.
patent: 2002/0151555 (2002-10-01), Barvian et al.
patent: 2002/0151558 (2002-10-01), Andrianjara et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2002/0156069 (2002-10-01), Picard et al.
patent: 2002/0161000 (2002-10-01), Barvian et al.
patent: 2002/0193377 (2002-12-01), Andrianjara et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2003/0078276 (2003-04-01), Andrianjara et al.
patent: 2003/0087924 (2003-05-01), Sorenson
patent: 2003/0130278 (2003-07-01), Gaudilliere et al.
patent: 2003/0144274 (2003-07-01), Bunker et al.
patent: 2003/0216402 (2003-11-01), Gaudilliere et al.
patent: 2003/0220355 (2003-11-01), Gaudilliere et al.
patent: 2004/0006077 (2004-01-01), Gaudilliere et al.
patent: 0 935 963 (1999-08-01), None
patent: 0 935 963 (1999-08-01), None
patent: 1 069 110 (2001-01-01), None
patent: 1 138 680 (2001-10-01), None
patent: WO 99/64400 (1999-12-01), None
patent: WO 00/09485 (2000-02-01), None
patent: WO 01/12611 (2001-02-01), None
patent: WO 01/63244 (2001-08-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064568 (2002-08-01), None
patent: WO 02/064571 (2002-08-01), None
patent: WO 02/064572 (2002-08-01), None
patent: WO 02/064578 (2002-08-01), None
patent: WO 02/064595 (2002-08-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 02/064599 (2002-08-01), None
patent: WO 03/032999 (2003-04-01), None
patent: WO 03/033478 (2003-04-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 04/0003322 (2003-12-01), None
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
U.S. Appl. No. 10/634,531, filed Aug. 5, 2003, Johnson.
U.S. Appl. No. 10/634,709, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,162, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,473, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,289, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,712, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,181, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,489, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,420, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,716, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,288, filed Aug. 5, 2003, O'Brien.
U.S. Appl. No. 10/634,717, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,177, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,290, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,182, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,419, filed Aug. 5, 2003, Hicks, et al.
U.S. Appl. No. 10/634,713, filed Aug. 5, 2003, Picard.
U.S. Appl. No. 10/634,225, filed Aug. 5, 2003, Picard et al.
U.S. Appl. No. 10/634,718, filed Aug. 5, 2003, Ortwine.
U.S. Appl. No. 10/739,261, filed Dec. 18, 2003, Bunker et al.
Billinghurst, et al., Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase, Arthritis & Rheumatism, 2000; 43(3): 664-672.
Billinghurst, et al., Enganced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage, J. Clin Invest., 1997; 99(7): 1534-1545.
Chen, et al., Structure-Based Design of a Novel, Potent, and selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design, J. Am. Chem. Soc., 2000; 122: 9648-9654.
Dahlberg, et al., Selective Enhancement of Collagenase-mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase2), Arthritis & Rheumatism, 2000; 43(3): 673-682.
Hirota, et al., Novel Synthesis of Pyrido [3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-catalyzed Oxidative Coupling, Heterocycles, 1994; 37(1): 563-570.
Lovejoy, et al., Crystal structures of MMP-1 AND -13 reveal the structural basis for selectivity of collagenase inhibitors, Nature Structural Biology, 1999; 6(3): 217-221.
Mitchell, et al., Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metaloproteinase-13 from Human Osteoarthritic, Cartilage, J. Clin. Invest., 1996; 97: 761-768.
Mokrosz, et al., Structure-activity relationship studies of CNS agents. Part 10(1): 1-Aryl-2-[3-(4-aryl-1-piperazinyl)propyl]-1,4-dihydro-3(2H)-isoquino linones:two modes of the interaction with the 5-HTIA receptor site. Pharmazie, 1994; 49(5): 328-33.
Moy, et al., High-resolution Solution Structure of the Cataliytic Fragment of Human Collagenase-3 (MMP-3) Complexed with a Hydroxamic Acid Inhibitor, J. Mol. Biol., 2000; 302: 671-689.
Neuhold, et al., Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice, J. Clin. Invest., 2001; 107(1): 35-44.
Wernicke, et al, “Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoif Arthritis and Osteoarthritis”, The Journal of Rheumatology, 1996, vol. 23, No. 4, pp. 590-595.
Reboul, et al “The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes”, J. Clin. Invest., vol. 97, No. 9, May 1996 pp. 2201-2019.
Freemont, et al, “In situ zymographic localisation of type II collagen degrading activity in osteorthritic human articular cartilage”, Ann. Rheum. Dis., 1999, vol. 58, pp. 357-365.
Bunker Amy Mae
Sliskovic Drago Robert
Ashbrook Charles W.
Pfizer Inc.
Purchase, Jr. Claude F.
Rao Deepak
Warner-Lambert Company LLC
LandOfFree
3-isoquinolinone derivatives as matrix metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-isoquinolinone derivatives as matrix metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-isoquinolinone derivatives as matrix metalloproteinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487100